• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • BPC-157 / TB-500 Blend – Research Compound Profile

    BPC-157 / TB-500 Blend – Research Compound Profile

    Category: Recovery Research | Molecular Type: Peptide Blend (Pentadecapeptide + 43-Amino-Acid Fragment) | Research Status: Extensive Preclinical Data; Limited Human Pilot Data

    This page compiles published research data for qualified researchers. The BPC-157 / TB-500 blend is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation.

    Purchase for Research →

    Molecular Overview

    BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide (amino acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) originally isolated from human gastric juice. It has been the subject of over 100 preclinical studies across a wide range of tissue-repair and cytoprotective models [1][2]. BPC-157 is notably stable in human gastric juice for over 24 hours, a characteristic that distinguishes it from other growth factor peptides that are rapidly degraded in the gastrointestinal environment [2]. Structurally, the run of proline residues and a tandem Asp-Asp pair give the molecule a compact, acidic character with no cysteine, methionine, or tryptophan to serve as oxidation-prone liabilities.

    TB-500 is a synthetic peptide corresponding to the biologically active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein and one of the most abundant intracellular peptides in mammalian cells [3]. Thymosin Beta-4 functions as a G-actin monomer-sequestering protein that regulates actin polymerization dynamics, directly influencing cell shape, motility, and migration [4][6]. The peptide retains an N-terminal Ac-LKKTETQ sequence responsible for its actin-binding and cell-migration activity. The combination of these two peptides in a 1:1 blend represents a research approach targeting complementary stages of the wound-healing cascade [5][6].

    Mechanism of Action

    BPC-157

    The primary mechanism of BPC-157 centers on the VEGFR2-Akt-eNOS signaling cascade. Published research demonstrates that BPC-157 activates vascular endothelial growth factor receptor 2 (VEGFR2) and promotes its internalization within endothelial cells, triggering downstream phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) [5][17]. This pathway drives angiogenesis — the formation of new blood vessels at injury sites — a process fundamental to tissue repair across multiple organ systems.

    Beyond angiogenesis, BPC-157 has been shown to modulate the nitric oxide (NO) system bidirectionally: published studies document that it counteracts both NO-blockade (L-NAME-induced) and NO-overproduction (L-arginine excess) disturbances, effectively maintaining NO homeostasis in injury models [13]. At the gene expression level, BPC-157 rapidly upregulates early growth response gene-1 (egr-1) and its co-repressor nab2, creating a controlled feedback axis that transactivates downstream targets including collagen, PDGF, and cytokine genes critical for organized wound repair [2]. BPC-157 also activates the FAK-paxillin signaling pathway, which governs focal adhesion dynamics in migrating cells — rat Achilles tendon explant studies demonstrated significantly accelerated fibroblast outgrowth and cytoskeletal reorganization following BPC-157 exposure [18].

    Pharmacokinetic analysis by Wang et al. (2022) determined that BPC-157 has an elimination half-life of less than 30 minutes following systemic administration, with hepatic metabolism and renal clearance as the primary elimination pathways [15]. Despite this short systemic half-life, the peptide remains detectable and active within wound sponge exudates for several hours, suggesting local tissue retention at injury sites [2].

    TB-500 (Thymosin Beta-4 Fragment)

    TB-500’s primary molecular function is as a G-actin monomer-sequestering protein. By binding monomeric actin at a 1:1 ratio, it regulates actin polymerization dynamics and thereby directly controls cell shape, motility, and migration [4][6]. This actin-regulatory mechanism is particularly relevant at wound sites, where cell migration is the rate-limiting step in tissue repair. Published research shows that TB-500 upregulates matrix metalloproteinases (MMPs) that degrade extracellular matrix barriers, enabling keratinocytes, endothelial cells, and fibroblasts to migrate into the wound bed [3].

    TB-500 also functions as an anti-inflammatory peptide by reducing pro-inflammatory cytokines (IL-1β, TNF-α) and suppressing NF-κB activation, which modulates the inflammatory phase of wound healing [6].

    Synergistic Rationale

    The combination of BPC-157 and TB-500 targets complementary and overlapping stages of the wound-healing cascade as described in published literature. During the initial inflammatory phase of standard wound-healing models, BPC-157 modulates NO and inflammatory mediator balance while TB-500 downregulates NF-κB-driven inflammation. In the proliferative phase, BPC-157 drives VEGF-mediated angiogenesis and fibroblast activation at the local injury site, while TB-500 mobilizes progenitor cells and promotes their migration into the repair zone through actin cytoskeleton reorganization. During the remodeling phase, both peptides support organized collagen deposition — BPC-157 via egr-1/nab2 gene regulation and TB-500 through extracellular matrix remodeling via MMP pathways [5][6].

    Published Research Parameters

    The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

    Study / YearModelDurationKey ObservationReference
    Seiwerth et al., 2021Rat (Achilles tendon transection, MCL transection)Multiple weeksImproved biomechanical strength and histological healing scores with enhanced collagen organization and neovascularization[1]
    Malinda et al., 1999Mouse (full-thickness dermal wounds)Days post-woundingAccelerated wound closure vs. controls; enhanced collagen deposition and angiogenesis[4]
    Chang et al., 2011Rat (Achilles tendon explant, in vitro/in vivo)VariableEnhanced tendon fibroblast outgrowth, cell survival, and cytoskeletal reorganization[18]
    Gwyer et al., 2021Human (case series, knee pain patients)Case seriesFavorable outcomes reported in multiple types of knee pain[11]
    Safety Pilot, 2025Human (2 healthy adults)Pilot studyNo adverse effects on cardiac, hepatic, renal, thyroid, or hematological biomarkers[14]
    Wang et al., 2022Rat (pharmacokinetic study)PK studyElimination half-life <30 minutes; hepatic metabolism, renal clearance[15]

    Stability & Storage Characteristics

    Published data and manufacturer specifications indicate the following stability characteristics for BPC-157 and TB-500:

    • Lyophilized stability: Both peptides in lyophilized (freeze-dried) form retain stability for 12+ months when stored at −20 °C (−4 °F) in a dry, light-protected environment. Repeated temperature fluctuations should be avoided, as freeze-thaw cycles degrade peptide integrity.
    • BPC-157 gastric stability: A distinctive characteristic of BPC-157 is its stability in human gastric juice for over 24 hours, in contrast to other growth factor peptides that undergo rapid enzymatic degradation in the gastrointestinal environment [2].
    • Pharmacokinetic characteristics: BPC-157 demonstrates a systemic elimination half-life of less than 30 minutes [15], yet local tissue retention at wound sites has been documented for several hours in wound sponge exudate studies [2].
    • Degradation chemistry: As an actin-sequestering peptide with an internal Cys residue, TB-500/Tβ4 is susceptible to oxidation of that thiol group, which is one recognized route of activity loss during prolonged storage in solution; low-oxygen, cold-chain handling minimizes this risk. BPC-157’s aspartate-rich region is separately susceptible to slow succinimide/iso-aspartate rearrangement under thermal stress.

    Analytical Characterization

    Because this product is a two-component blend, quality control requires resolving and quantifying each peptide independently rather than relying on a single combined assay. Reverse-phase HPLC with a gradient suited to both a compact 15-residue peptide and a larger 43-residue fragment provides orthogonal purity data for each component and can resolve co-eluting degradation products. Electrospray mass spectrometry confirms the intact mass of each peptide against its theoretical value and detects truncation, oxidation (particularly relevant to TB-500’s internal cysteine), or deamidation products. A peptide-content assay for each component distinguishes net peptide mass from shared excipients, counter-ion, and residual solvent, since a single gravimetric measurement of the blended lyophilizate cannot apportion mass between the two actives. The available lot documentation for a validated blend should report independent purity and identity data for both BPC-157 and TB-500, not a single composite figure.

    Key Published Research Findings

    The following findings are derived from peer-reviewed publications. Each observation is attributed to its source study.

    • Tendon and ligament repair: In a 2021 comprehensive review published in Frontiers in Pharmacology, Seiwerth et al. documented that BPC-157 significantly improved biomechanical strength and histological healing scores in rat Achilles tendon transection and medial collateral ligament transection models, with enhanced collagen organization and neovascularization [1]. Separately, Chang et al. (2011) demonstrated in a Journal of Applied Physiology study that BPC-157 promoted tendon fibroblast outgrowth, cell survival, and cytoskeletal reorganization in rat Achilles tendon explant cultures [18].

    • Dermal wound healing: In a landmark 1999 study published in the Journal of Investigative Dermatology, Malinda et al. observed that Thymosin Beta-4 applied topically to full-thickness dermal wounds in mice accelerated wound closure compared to vehicle controls, with increased collagen deposition, enhanced keratinocyte migration, and improved angiogenesis [4].

    • Anti-inflammatory activity: Xing et al. (2021) reviewed in Frontiers in Endocrinology that Thymosin Beta-4 suppressed NF-κB activation and reduced pro-inflammatory cytokine levels (TNF-α, IL-1β) across corneal, dermal, and cardiac injury models [6]. Maar et al. (2021) further discussed TB-4’s regenerative potential through embryonic pathway reactivation in adult tissue repair contexts [3].

    • Bone fracture healing: Seiwerth et al. (2021) reported that BPC-157 improved healing in segmental bone defect models, with enhanced callus formation and vascularization in preclinical models [1].

    • Human case data: Gwyer et al. (2021) published a case series in Alternative Therapies in Health and Medicine describing favorable outcomes following intra-articular BPC-157 administration for multiple types of knee pain [11]. A 2025 pilot study documented no adverse effects following IV BPC-157 infusion in two healthy adults [14].

    • VEGF and angiogenesis pathways: Jozwiak et al. (2025) and Sikiric et al. (2025) comprehensively reviewed BPC-157’s multifunctional mechanisms in Pharmaceuticals, detailing VEGFR2-Akt-eNOS pathway activation, NO system modulation, and the peptide’s role in angiogenesis and cytoprotection [5][17].

    Regulatory Status

    • FDA status: Neither BPC-157 nor TB-500 (Thymosin Beta-4) has been approved by the FDA for human therapeutic use. These compounds are classified as research chemicals.
    • Clinical trials: A clinical trial investigating Thymosin Beta-4 in acute myocardial infarction (NCT05485818) has been registered on ClinicalTrials.gov [9].
    • Sports anti-doping: Both BPC-157 and TB-500 are prohibited in competitive sports by the World Anti-Doping Agency (WADA) and the U.S. Anti-Doping Agency (USADA). USADA issued an advisory in 2024 regarding BPC-157’s prohibited status and associated risks for competitive athletes [16].
    • Research use only: This compound is sold exclusively for research purposes. All applicable laws, regulations, and institutional guidelines must be followed.

    References

    1. Frontiers in Pharmacology (2021) — Seiwerth S, et al. “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.” Comprehensive review of BPC-157 wound healing across skin, tendon, ligament, and bone models. View Source

    2. Current Pharmaceutical Design (2018) — Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Review of GI protective effects and mechanism of action. View Source

    3. International Journal of Molecular Sciences (2021) — Maar K, et al. “Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State.” Regenerative potential of TB-4. View Source

    4. Journal of Investigative Dermatology (1999) — Malinda KM, et al. “Thymosin β4 accelerates wound healing.” Landmark study demonstrating accelerated dermal wound closure in mice. View Source

    5. Pharmaceuticals (2025) — Jozwiak M, et al. “Multifunctionality and Possible Medical Application of the BPC 157 Peptide.” Comprehensive review of BPC-157 mechanisms including VEGF and NO pathways. View Source

    6. Frontiers in Endocrinology (2021) — Xing Y, et al. “Progress on the Function and Application of Thymosin β4.” Review of Tβ4 roles in cell migration, angiogenesis, and anti-inflammation. View Source

    7. Orthopaedic Journal of Sports Medicine (2025) — Rivera MJ, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” Systematic review of musculoskeletal applications. View Source

    8. ClinicalTrials.gov (2022) — “Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.” NCT05485818 — human cardiac trial. View Source

    9. Alternative Therapies in Health and Medicine (2025) — “Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study.” IV BPC-157 in 2 healthy adults with no adverse effects. View Source

    10. Pharmacokinetics of BPC-157 (2022) — Wang L, et al. “Pharmacokinetics, distribution, metabolism, and excretion of body protective compound-157.” Elimination half-life below 30 minutes; hepatic metabolism and renal clearance. View Source

    11. USADA (2024) — “BPC-157: Experimental Peptide Creates Risk for Athletes.” Advisory on BPC-157 prohibited status and associated risks for competitive athletes. View Source

    12. Pharmaceuticals (2025) — Sikiric P, et al. “BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions.” Detailed analysis of VEGFR2-Akt-eNOS pathway activation. View Source

    13. Journal of Applied Physiology (2011) — Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Tendon fibroblast migration and cytoskeletal reorganization. View Source


    ⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The BPC-157 / TB-500 blend is sold exclusively as a research compound and has not been approved by the FDA for human consumption or use. Both compounds are prohibited by WADA and USADA in competitive sports. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

    Purchase BPC-157 / TB-500 Blend for Research →